Mosunetuxumab/Polatuzmab Vedotin Combo Advances R/R LBCL Treatment
A recent study has shown that the combination of mosunetuzumab and polatuzumab vedotin brings significant improvements to patients with relapsed large B-cell lymphoma, providing them with a chemotherapy-free treatment option.
Study Details
The phase 3 SUNMO study (NCT05171647) revealed that administering mosunetuzumab-axgb (Lunsumio) and polatuzumab vedotin-piiq (Polivy) subcutaneously led to statistically significant and clinically meaningful enhancements in progression-free survival (PFS) and objective response rate (ORR) for patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) who are not eligible for transplant.
At a median follow-up of 23.2 months, the combination of mosunetuzumab and polatuzumab vedotin demonstrated a 59% reduction in the risk of disease progression or death compared with the standard treatment. The median PFS for patients receiving the novel combination was 11.5 months, a significant increase compared to the control group.
Results
The combination also showed a superior ORR, with more patients achieving an objective response and a notably higher complete response rate compared to the standard treatment. Patients who achieved a complete response with the combination therapy had a higher rate of remission after one year.
Furthermore, the safety profile of the mosunetuzumab and polatuzumab vedotin combination was favorable, with low rates of certain adverse events and fewer treatment discontinuations compared to the standard treatment group.
Conclusion
The mosunetuzumab and polatuzmab vedotin combination offers a promising chemotherapy-free treatment option for patients with relapsed large B-cell lymphoma. Its fixed-duration administration and potential for outpatient use could greatly benefit patient access and convenience.
The endorsement of this combination by the National Comprehensive Cancer Network (NCCN) further solidifies its place in the treatment landscape, offering patients a well-tolerated alternative to traditional chemotherapy.
